Cannabis one of the most commonly used and abused illicit substances may produce harmful effects in some individuals. In laboratory studies, we have shown that Delta-9-tetrahydrocannabinol (d-9rTHC) induced transient but clinically significant psychotomimetic and amnestic effects in some but not all carefully screened healthy individuals. Epidemiological data suggest that cannabis is a modest risk for the emergence of psychosis and psychotic disorders. Further, a recent report suggests that polymorphisms of the gene for the enzyme catechol-O-methyltransferase (COMT) might moderate the risk of psychosis following cannabis exposure. COMT Val108/58Met polymorphism moderates executive function and the physiology of the prefrontal cortex in humans and is indirectly associated with increased mesolimbic dopamine transmission. Cannabinoids have been shown to increase dopaminergic transmission both in the prefrontal cortex and striatum, and these effects might contribute to the psychotomimetic and amnestic effects of cannabinoids. Similarly, hippocampal GABAergic systems may contribute to the psychotomimetic and amnestic effects of cannabinoids. Hypotheses: Polymorphisms of the genes for COMT and GABRA2 moderate the psychotomimetic and amnestic response to d-9-THC. Methods: 81 healthy subjects (27 each of val-val, val-met and met-met genotype) will complete 2 test days during which they will receive d-9-THC (placebo or 2.5 mg) intravenously over 20 minutes in randomized counterbalanced fashion under double-blind conditions. Primary outcomes include psychotomimetic effects (PANSS positive symptoms subscale) and total immediate recall and delayed free deficits (Rey Auditory Verbal Learning Test) will be measured. Secondary outcomes include measures of spatial working memory, delayed recognition memory and attention. Results: Pilot data (n=15) show that otherwise healthy individuals homozygous for 1) the COMT Val108/58Met allele (Val-Val) and 2) the """"""""tt"""""""" genotype of a SNP marker (rs279858) of the GABRA2 gene, are more vulnerable to experience clinically significant psychotomimetic and amnestic effects induced by d-9-THC. ? ? ?
| Ranganathan, Mohini; Radhakrishnan, Rajiv; Addy, Peter H et al. (2017) Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information. Prog Neuropsychopharmacol Biol Psychiatry 79:176-183 |
| Sherif, Mohamed; Radhakrishnan, Rajiv; D'Souza, Deepak Cyril et al. (2016) Human Laboratory Studies on Cannabinoids and Psychosis. Biol Psychiatry 79:526-38 |
| Wilkinson, Samuel T; Yarnell, Stephanie; Radhakrishnan, Rajiv et al. (2016) Marijuana Legalization: Impact on Physicians and Public Health. Annu Rev Med 67:453-66 |
| Gupta, Swapnil; Ranganathan, Mohini; D'Souza, Deepak Cyril (2016) The early identification of psychosis: can lessons be learnt from cardiac stress testing? Psychopharmacology (Berl) 233:19-37 |
| Cortes-Briones, Jose A; Cahill, John D; Skosnik, Patrick D et al. (2015) The psychosis-like effects of ?(9)-tetrahydrocannabinol are associated with increased cortical noise in healthy humans. Biol Psychiatry 78:805-13 |
| Wilkinson, Samuel T; Radhakrishnan, Rajiv; D'Souza, Deepak Cyril (2014) Impact of Cannabis Use on the Development of Psychotic Disorders. Curr Addict Rep 1:115-128 |
| Spaderna, Max; Addy, Peter H; D'Souza, Deepak Cyril (2013) Spicing things up: synthetic cannabinoids. Psychopharmacology (Berl) 228:525-40 |
| Sewell, R Andrew; Schnakenberg, Ashley; Elander, Jacqueline et al. (2013) Acute effects of THC on time perception in frequent and infrequent cannabis users. Psychopharmacology (Berl) 226:401-13 |
| D'Souza, Deepak Cyril; Fridberg, Daniel J; Skosnik, Patrick D et al. (2012) Dose-related modulation of event-related potentials to novel and target stimuli by intravenous ??-THC in humans. Neuropsychopharmacology 37:1632-46 |
| D'Souza, Deepak Cyril; Sewell, Richard Andrew; Ranganathan, Mohini (2009) Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci 259:413-31 |
Showing the most recent 10 out of 21 publications
